NCT03173391View on ClinicalTrials.gov

Long-term Efficacy and Safety of HMS5552 in T2DM Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

463

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

HMS5552

BID Oral administration

DRUG

Placebo

BID Oral administration

Trial Locations (1)

201203

Hua Medicine Limited, Shanghai

Sponsors
All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Hua Medicine Limited

INDUSTRY

NCT03173391 - Long-term Efficacy and Safety of HMS5552 in T2DM Subjects | Biotech Hunter | Biotech Hunter